Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix

David Gonzalez-Barcena, Raquel Bañuelos Alvarez, Elizabeth Pere Ochoa, Imelda Cardenas Cornejo, Ana M. Comaru-Schally, Andrew S. Schally, Juergen Engel, Thomas Reissmann, Hilde Riethmüller-Winzen

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

The efficacy of the luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) in the medical management of uterine leiomyomas (fibromas) was evaluated. Cetrorelix was administered to 18 pre-menopausal women with myomas with a mean age of 33.3 years, who had been candidates for hysterectomy. The initial dose of Cetrorelix was 5 mg twice daily s.c. for the first 2 days and thereafter 0.8 mg was given twice daily s.c. for at least 3 months. The mean duration of the treatment was 4.4 months. Before the therapy with Cetrorelix, the mean uterine volume, measured by ultrasonography, was 395.4 ± 69.2 ml (range 89-1166). Sixteen patients showed a progressive reduction in uterine volume from 410.4 ± 77.1 to a mean of 230.8 ± 52.6 ml at 3 months. All patients became amenorrhoeic and had hot flushes. After treatment with Cetrorelix, a surgical myomectomy was performed in 12 women. One of the patients subjected to myomectomy after therapy with Cetrorelix became pregnant. These patients have been followed for up to 25 months and only in one case has the uterine volume increased after therapy. Three patients had good responses to therapy with Cetrorelix and it was decided to follow them only by observation. One patient became pregnant 2 months later. In the other patient, the uterine volume remained unchanged for the duration of the follow-up of 2 years and the third patient showed an increase after 21 months. In three patients, it was necessary to perform total hysterectomy. In 14 patients, serum concentrations of luteinizing hormone, follicle stimulating hormone and oestradiol decreased after the administration of the first dose of Cetrorelix and continued at subnormal values throughout therapy. In 15 patients who were not subjected to total hysterectomy, menstrual function returned at 1 month after cessation of treatment. Overall results support the use of Cetrorelix for the management of uterine leiomyomas.

Original languageEnglish (US)
Pages (from-to)2028-2035
Number of pages8
JournalHuman Reproduction
Volume12
Issue number9
DOIs
StatePublished - 1997
Externally publishedYes

Keywords

  • Cetrorelix
  • Hysterectomy
  • LH-RH antagonist
  • Uterine leiomyomas

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynecology
  • Reproductive Medicine

Fingerprint Dive into the research topics of 'Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix'. Together they form a unique fingerprint.

Cite this